Human Papillomavirus (High Risk Only)
Expected Turnaround Time
1-3 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
The Aptima HPV assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens. The high-risk HPV types detected by the assay include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
Requisition Forms
Specimen Requirements
Specimen Requirements
Cervical Cells: 2 mL, ThinPrep® or SurePath™
Specimen Stability
- ThinPrep: 105 days (not above 8°C more than 30 days)
- SurePath: 21 Days
Storage Requirements
2°C to 30°C
Shipping Conditions
Ambient
Specimen Rejection Criteria
Insufficient specimen; Low sample cellularity
Test Details
Keywords
Pathology, Gynecologic cancer, Molecular Diagnostics, Oncology, Women's Health, STI
Test Method
Transcription-Mediated Amplification (TMA)
Methodology Category
Molecular
Regulatory Status
IVD